A punitive “clawback” rate, which forces drugmakers to repay up to a third of their UK revenues to the NHS, is a major factor driving investment out of the country. The pharmaceutical industry is demanding that this rate be reduced to single digits, similar to levels in other European nations, to restore the UK’s competitiveness.
This revenue reclaim scheme, combined with low overall spending on medicines, has created what one executive called a “terrible” market. Companies argue that the high clawback makes the UK an unpredictable and unprofitable place to do business, directly impacting decisions on where to locate R&D facilities and run clinical trials.
The real-world consequences are now impossible to ignore. MSD has scrapped a £1bn research hub, Eli Lilly has paused a new lab, and Sanofi has halved its clinical trial activity in the UK. These are not isolated decisions but a collective response to a financial environment the industry views as unsustainable.
With the government reportedly attempting to restart talks on drug pricing, the clawback rate will be a key point of contention. Industry leaders maintain that a significant reduction is non-negotiable if the UK wants to halt the exodus of investment and secure its future as a leader in the global life sciences sector.
